Medtronic, FDA Approval of CGMS iPro Continuous Glucose Recorder

January 29, 2008 — Medtronic, Inc. (NYSE: MDT) announced the FDA approval of a new physician-use continuous glucose monitoring (CGM) system, the CGMS® iPro™ Recorder. Physicians send patients home with the CGMS iPro Recorder to uncover patterns and potential problems that often go undetected with today’s standard glucose measurements like finger stick meters and HbA1c tests... Medtronic's Press Release-

Arena Pharmaceuticals, APD668, Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes

Jan 07, 2008 - Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced that initial clinical study results for APD668, an oral drug candidate discovered by Arena and being investigated for the treatment of type 2 diabetes under a partnership with Ortho-McNeil Pharmaceutical, Inc., suggest that Glucose-Dependent Insulinotropic Receptors, or GDIRs, may improve glucose control in patients with type 2 diabetes... Arena's Press Release-

Daiichi Sankyo's Welchol, FDA Approval to Reduce Blood Glucose in Adults With Type 2 Diabetes

January 21, 2008 - Daiichi Sankyo, Inc. announced that the United States Food and Drug Administration (FDA) has approved Welchol (colesevelam HCl) to improve glycemic control (measured as hemoglobin A1C) in adults with type 2 diabetes mellitus in combination with metformin, sulfonylureas, or insulin, either alone or in combination with other anti-diabetic agents. Welchol is now the first and only medication approved to reduce both glucose levels and low density lipoprotein cholesterol levels (LDL-C)... [PDF] Daiichi Sankyo's Press Release-

Tissera , Curative Effect of Its Transplantation Technology in Large Animal Diabetic Model

Tuesday, 8 January 2008 - Tissera, Inc. (OTCBB: TSSR ) reports the achievement of a significant milestone in its ongoing large animal diabetic model experiments of pancreatic xenotransplantation , designed for the future treatment of insulin-dependent (type I) diabetes mellitus.
Based on the previously reported positive results obtained in pancreatic transplantation experiments in normal non human primates, Tissera's sponsored research team at the Weizmann Institute of Science has moved forward to investigate in diabetic non human primates the functional and therapeutic value of the company's approach. In these studies, non human primates are treated by an agent called streptozotocin which induces them to become diabetic and consequently dependent upon administration of exogenous insulin for the maintenance of reasonable blood sugar levels. After allowing a few weeks for stabilization, appropriately timed pig embryonic pancreatic tissue is transplanted into the diabetic primate, which is thereafter intensively and carefully followed... Tissera's Press Release-

Incyte, HM74a agonist program for type 2 diabetes

Jan. 8, 2008--Incyte Corporation (Nasdaq:INCY) will announce at the 26th Annual JPMorgan Healthcare Conference further positive clinical proof-of-concept results for several of its wholly-owned, internally developed programs, including its JAK inhibitor for rheumatoid arthritis, myelofibrosis and psoriasis, as well as its 11-beta hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor for type 2 diabetes. During the JPMorgan presentation, the Company will also introduce its HM74a agonist program for type 2 diabetes and review the key objectives for all its lead programs in 2008... Incyte's Press Release-

Echo Therapeutics, Clinical Study of Its Symphony Continuous Transdermal Glucose Monitoring System

Jan. 2 , 2008 - Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE ) announced that it has started the second clinical study of its current Symphony(TM) Continuous Transdermal Glucose Monitoring System (CTGM System) at the Tufts-New England Medical Center (Tufts-NEMC). The Company expects to announce the results of the study in the first quarter of 2008. Echo's current generation Symphony CTGM System consists of the FDA-cleared SonoPrep skin permeation device that incorporates patented and leading-edge permeation control technology, together with wireless conductivity and proprietary transdermal sensor technologies... [PDF] Echo Therapeutics' Press Release-

DexCom, Joint Development Agreement with Animas Corporation

January 10, 2008 - DexCom, Inc. (NASDAQ: DXCM), a leading provider of continuous glucose monitoring systems for people with diabetes, announced that it has entered into a joint development agreement with Animas Corporation to integrate DexCom's continuous glucose monitoring (CGM) technology into Animas® insulin pumps... DexCom's Press Release-

BodyTel, GlucoTel Technical Files for CE Certification

January 8, 2008 - BodyTel Scientific Inc., (OTCBB:BDYT) the developer of wireless telemedical measuring devices, announced that its wholly owned subsidiary BodyTel Europe GmbH, legal manufacturer of the blood glucose monitoring and diabetes management system GlucoTel, has submitted the GlucoTel Technical File for regulatory review to the designated European Notified Body... BodyTel's Press Release-

Insulet and DexCom , Development Agreement

January 7, 2008 - Insulet Corporation (NASDAQ: PODD), the leader in wearable insulin pump technology with its OmniPod Insulin Management System, and DexCom, Inc. (NASDAQ: DXCM), a leading provider of continuous glucose monitoring systems for people with diabetes, announced they have signed a development agreement to integrate DexCom's continuous glucose monitoring technology into the wireless, handheld OmniPod System Personal Diabetes Manager (PDM). In addition to programming the patient's insulin delivery, the PDM with integrated DexCom technology will receive and display continuous glucose readings from DexCom's wearable sensor transmitter... DexCom's Press Release - Insulet's Press Release -

VIVUS , Extension Study with Qnexa for Diabetes

Jan 09, 2008 - VIVUS, Inc (NASDAQ: VVUS) a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, announced it has initiated a six-month extension study for patients currently enrolled in the OB-202 diabetes study. The OB-202 study is a 28 week, randomized, double blind, placebo controlled, efficacy and safety study of Qnexa(TM) in the glycemic management of obese Type 2 diabetics. The newly initiated study, DM-230, will allow subjects to continue, in a blinded fashion as randomized, in the study for an additional 28 weeks... VIVUS ' Press Release -

DiObex, Patent for the Prevention of Insulin-Induced Hypoglycemia

January 8, 2008 - DiObex, Inc., a privately held biotechnology company developing treatments for metabolic diseases, announced that it has secured a critical patent from the U.S. Patent and Trademark Office for the use of very low dose glucagon, or DIO-901 , in the prevention of insulin-induced hypoglycemia in diabetes patients. The patent grants DiObex exclusive rights to methods of reducing the risk of hypoglycemia in diabetes patients being treated with insulin by administering very low doses of glucagon... DiObex' Press Release-

DIAMYD, PHASE III TRIAL WITH DIABETES VACCINE

December 21, 2007 – Diamyd Medical announced today that it has filed an Investigational New Drug (IND) application for a pivotal US Phase III clinical trial with the Diamyd® therapeutic vaccine in recent onset type 1 diabetes patients. The application was submitted to the US Food and Drug Administration (FDA)... The Diamyd® therapeutic vaccine is intended to arrest or slow down the autoimmune destruction of insulin producing beta cells in type 1 diabetes... Diamyd's Press Release -

Adolor , Phase 2a Study of Delta Agonist ADL5859 in Neuropathic Pain

Dec. 14, 2007--Adolor Corporation (Nasdaq: ADLR) announced the initiation of a third Phase 2a study of ADL5859, a novel Delta opioid agonist in development for the treatment of pain. Study 33CL231 will explore the analgesic efficacy of ADL5859 in treating pain associated with diabetic peripheral neuropathy . Recently, Adolor and Pfizer Inc (NYSE: PFE) entered into a collaboration... Adolor's Press Release -